Remepy
PrivateLast Round
Series A
Aug 12, 2026
Total Funding Raised
$51M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Remepy is a biotechnology company that develops hybrid drugs, which combine traditional medications with digital therapeutic software to enhance treatment effectiveness.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical AI, Patient Engagement
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remepy Comparables
Compare Remepy with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amalgam Rx | 78% | |
| Click Therapeutics | 78% | |
| Newel Health | 74% |
Remepy Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 12, 2026 | ||||
| Seed | May 1, 2024 |
Key People
Founding team and executive leadership
Remepy Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vine Ventures | Series A, Seed |
| NFX | Series A, Seed |
| Fresh.Fund | Pre Seed, Series A, Seed |
| Firstime | Seed |
| IT-Farm Corporation | Series A |
| StageNext Fund | Pre Seed, Seed |
| Qumra Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 64% MoM, reaching 6.2K.
- Aug 12, 2026
$36M round led by M Ventures and O.G. Venture Partners.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Remepy, Inc. will develop Hybrid Drugs on Oct 1st '26.
- hiresSep 16, 2026
Remepy, Inc. appoints Eran Harary, MD, as Chief Medical Officer effective Oct 1st '26 in New York, adding him to its executive management team to advance clinical development, trial execution, and medical and regulatory engagement across its Hybrid Drug pipeline.
- is_developingAug 13, 2026
Remepy, Inc. is developing Hybrid Drugs on Jul 1st '25.
- is_developingAug 13, 2026
Remepy, Inc. is developing hybrid drugs for multiple indications on Aug 1st '26.
- receives_financingAug 13, 2026
Remepy, Inc. received financing of $36M in Series A on Aug 13th '26.
Remepy Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Remepy's valuation, stock price, and market status.
Is Remepy a public or private company?
Remepy is a private company.
What is the current stock price of Remepy?
Remepy is a private company, so its shares have no public market price. Caplight tracks Remepy's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Remepy worth (valuation)?
Valuation information for Remepy is not publicly available.
Can I buy Remepy stock?
Remepy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Remepy's last funding round?
Remepy's most recent funding round was Series A on August 12, 2026.
Who are the main investors in Remepy?
Key investors in Remepy include NFX, TechAviv, M Ventures, O.G. Venture Partners.
Will Remepy IPO soon?
No public IPO plans have been announced for Remepy.
How can I track Remepy secondary market activity?
Caplight tracks bids, offers, and trades in Remepy's shares on secondary markets.